



Press release

Towards a personalized medicine for all cancer patients: Cerba HealthCare and Oncomedics announce the signature of a partnership for the clinical implementation of the Oncogramme[®], an assay dedicated to the real-life prediction of chemotherapy efficacy.

Issy les Moulineaux and Limoges – France, 17 December 2018.

Emerging from a French academic research initiative (Limoges University and University Hospital), the Oncogramme[®] is a functional assay predicting the anticancer activity of chemotherapies, alone or in combination with targeted therapies. Their efficacy is measured *ex vivo* on a patient's tumour sample, using Oncomedics' proprietary processes and reagents. The Oncogramme[®] produces a unique chemosensitivity profile for the patient at no risk, since each step is performed *in vitro*. This technology assists clinicians in identifying the most appropriate treatment against their patients' cancers, especially for those not eligible to targeted therapies.

Thanks to this close partnership, Oncomedics will benefit from Cerba HealthCare's technical, scientific and medical expertise to complete the assay's development and improve its strategy (market access, commercial deployment) to ensure a seamless insertion within the clinical setting.

"Oncomedics wants to accelerate accessibility of the Oncogramme[®] to all cancer patients. Cerba HealthCare's experience in medical analysis will allow our company to achieve the industrial development of the Oncogramme[®]. Their vast network of laboratories will greatly ease the access to a global market for Oncomedics, and thus the commercial deployment of the Oncogramme[®]", explains Christophe LAUTRETTE, founder and CEO of Oncomedics.

"We are pleased to integrate Oncomedics into our open innovation strategy, through which we accompany the development of ground-breaking companies. The added value of Oncomedics' technology, offering a personalized treatment to all cancer patients, including those who cannot benefit from targeted therapies, is in line with our dedication to provide access to the most innovative and performing health care solutions", says Jérôme SALLETTE, Director, Innovation and Development, at Cerba HealthCare.

About ONCOMEDICS

As a French innovative SMB, Oncomedics wants to offer each cancer patient an effective treatment against their disease. To achieve this goal, the company has developed and validated the Oncogramme[®], an *In Vitro* Diagnostics Medical Device (IVD-MD) that is already CE-marked for metastatic colorectal cancer (mCRC) as a first indication. The Oncogramme[®] measures *in vitro* the efficacy of drugs or drug associations (chemotherapies, targeted therapies) directly on a patient's own tumour cells. For mCRC patients, it boosts their chances to receive an effective treatment from 48 % (without the Oncogramme[®]) up to 84 % (with the Oncogramme[®]). Chemotherapies are hence transformed into targeted therapies available to all patients. Also, the fully standardized processes of the Oncogramme[®] make it the world's only assay adaptable to routine use in a medical laboratory, thereby reinforcing its accessibility. The Oncogramme[®] is currently being evaluated on breast and ovarian cancers through clinical studies, while its adaptation to other cancer pathologies is underway as part of the national project IMODI.

In addition, beyond the direct optimization of treatments, published medico-economic studies show that the use of functional assays such as the Oncogramme[®] may allow cost savings in cancer care superior to 26%; significantly, this figure does not consider additional health care costs generated by the highly detrimental side effects of cancer treatments.

<http://www.oncomedics.com>

About CERBA HEALTHCARE

As a European leader, the group is active on every segment of the medical biology market:

- routine medical biology, mainly in France, Belgium, Luxembourg and Italy, with more than 550 laboratories and 50 technical facilities;
- specialized medical biology, through a historical laboratory serving more than 50 countries in Europe, Africa and the Middle-East;
- biology for clinical trials, necessary for the proper development of new therapeutic molecules by the pharmaceutical and biotechnology industries, through subsidiary companies established on 5 continents;
- lastly, biology for diagnostic assays, allowing the *in vitro* diagnostics industry to validate new devices before their commercialization.

For the past 2 years, Cerba HealthCare has diversified its activities towards the veterinary genetics and biology market, with its dedicated subsidiary company Cerba Vet. The group employs more than 6,300 people, including more than 550 biologists.

<http://www.cerbahealthcare.com>

Contacts

CERBA HEALTHCARE
Pascale LAURENT
Directrice Communication
pascale.laurent@cerbahealthcare.com

ONCOMEDICS
Christophe LAUTRETTE, PhD
Président
christophe.lautrette@oncomedics.com